Try our Advanced Search for more refined results
Amgen Inc v. Genentech, Inc. et al
Case Number:
2:17-cv-07349
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 03, 2018
PTAB Shoots Down Pfizer's Bid To Review Avastin Patent
The Patent Trial and Appeal Board has turned down Pfizer Inc.'s challenge to a patent covering Genentech Inc.'s blockbuster cancer treatment Avastin, finding the challenger couldn't prove the patent shouldn't have been issued.
-
February 02, 2018
Amgen's Suit To Shield Cancer Treatment Biosimilar Tossed
A California federal judge on Friday granted a motion by Genentech to toss a complaint brought by Amgen seeking to invalidate more than two dozen patents related to Genentech's cancer treatment Avastin, finding that Amgen was bypassing a negotiation scheme required by law.
-
January 11, 2018
Amgen, Genentech Await Del. Ruling In Biosimilar IP Row
A California federal judge on Thursday tentatively paused Amgen's suit seeking to invalidate more than two dozen patents related to Genentech's cancer treatment Avastin, saying he wanted to see whether a Delaware court will transfer infringement actions that Genentech has filed over Amgen's biosimilar version of the drug.
-
October 27, 2017
Amgen 'Completely Ignoring' Biosimilar Law, Genentech Says
Amgen Inc. has been "completely ignoring" its information-disclosure obligations under the federal biosimilars law in order to shield its biosimilar of blockbuster cancer drug Avastin, Genentech Inc. claims in a newly unsealed complaint.
-
October 06, 2017
Amgen Sues Genentech To Shield Avastin Biosimilar
Amgen Inc. filed a suit in California federal court Friday seeking a declaration that 27 patents related to Genentech's cancer treatment Avastin are invalid, unenforceable and aren't infringed by Amgen's biologic, which won U.S. Food and Drug Administration approval last month.